Quratis

Name

Quratis

Website

https://quratis.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Quratis is a South Korea-based, KOSDAQ-listed biopharmaceutical company founded in 2016 that develops vaccines and cell therapies targeting tuberculosis, operating a dedicated bioplant in Osong with plans to scale for global pharmaceutical partnerships.

Ownership category

akta.pro rank

Product category

Tuberculosis Vaccines and Cell Therapies

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industries

Tuberculosis & Mycobacterial Diseases (HLAKAGAH), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ)

Keywords

• Tuberculosis vaccines
• Cell therapies
• Biopharmaceutical manufacturing
• Vaccine development
• Immunotherapy products

Headquarters

HQ city

Seocho

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Infrastructure, Operations

Core offering

Quratis develops vaccines and cell therapies for tuberculosis. It operates the Quratis Bioplant manufacturing site in Osong, North Chungcheong Province, South Korea, with plans to expand the site to support commercial production and enable future partnerships with global pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Tuberculosis vaccines and cell therapies

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Sanofi: Global vaccine major with an active tuberculosis vaccine R&D program and a large commercial vaccine franchise. Comparable to Quratis as an established player in the infectious disease vaccine space that Quratis could potentially partner with or supply through its Osong facility.
• GSK: Major vaccine developer historically active in TB (e.g., M72/AS01E candidate). Comparable as a large incumbent with deep vaccine R&D and global immunization distribution that Quratis's TB products would compete against or partner with.
• Serum Institute of India: World's largest vaccine manufacturer by doses, with significant TB vaccine engagement including prior BCG supply. Comparable as a global vaccine incumbent whose pricing and supply scale set the commercial bar Quratis would need to meet in TB.

Direct peers

• BioNTech: mRNA-based vaccine and cell therapy developer that has expanded into infectious disease vaccines beyond COVID-19. Comparable to Quratis as a biotech developing novel vaccine modalities targeting infectious diseases, including TB-related work.

Others

• Inventage Lab: Korean biotech with an explicit relationship to Quratis's Osong Bioplant site (planning to expand the facility). Comparable as an adjacent infrastructure/contract partner supporting Quratis's manufacturing scale-up.

Regional players

• GC Biopharma: Korean vaccine and blood-product manufacturer with global distribution. Comparable as a Korean-based vaccine manufacturer of similar regional scale that Quratis competes with for domestic capability and could partner with for distribution.
• SK Bioscience: Korean vaccine developer and manufacturer with a broad infectious disease pipeline and global commercial partnerships. Comparable to Quratis as a KOSDAQ-listed Korean vaccine company targeting global public health markets.
• EuBiologics: Korean vaccine company (KOSDAQ-listed) specializing in conjugate and travel vaccines. Comparable to Quratis as a fellow Korean publicly-listed vaccine developer with similar scale and emerging-market focus.

Emerging players

• Institut Pasteur Korea: Korean infectious disease research institute actively engaged in TB research. Comparable as a TB-focused research entity operating in Korea that Quratis may collaborate or compete with for talent and grants.
• Vir Biotechnology: Clinical-stage biotech developing immunotherapies and vaccines for infectious diseases. Comparable to Quratis as a development-stage peer targeting serious infectious diseases with novel biologic modalities.

Market position

Customer concentration

• LinkedInlinkedin.com/company/quratis

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quratis